Method
Level · gp.fundamentals.debt_to_revenue
Raw value 274.26% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTXeris Biopharma Holdings, Inc.'s latest supported as-filed period reports revenue of $92.1M, 28.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 274.26% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 8.97% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 28.74% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 87.87% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value 5.62% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 11.58% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Shares outstanding increased 12.9%; SBC / revenue moved 501 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 28.7%; Operating margin moved 65 bp lower; Operating income increased 15.4%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 28.7%; Operating margin moved 65 bp lower; Operating income increased 15.4%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 105.4%; Operating cash flow changed across a low base.
2 evidence-backed componentsShares outstanding changed +12.9% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
XERS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001867096-26-000077SEC ↗4Sep 1, 2026Period Sep 1, 20260002031695-26-000011SEC ↗4Sep 1, 2026Period Sep 1, 20260001652410-26-000018SEC ↗4Sep 1, 2026Period Sep 1, 20260001875714-26-000012SEC ↗4Aug 21, 2026Period Aug 1, 20260001867096-26-000073SEC ↗4Aug 21, 2026Period Aug 1, 20260001867096-26-000069SEC ↗4Aug 12, 2026Period Aug 12, 20260001875714-26-000009SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 12.02% · OPTIONAL
Revenue changed +28.7% from the comparable as-filed period.
Cash & equivalents changed +105.4% from the comparable as-filed period.
Current assets changed +48.1% from the comparable as-filed period.
Current liabilities changed +99.2% from the comparable as-filed period.
Selling, general & administrative changed +37.5% from the comparable as-filed period.
Research & development changed +32.5% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001867096-26-000065